Immunotherapy in Ovarian Cancer:(IGWHC)-Lupine Publishers
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjyKE1YOVOiTEwte0zAGNbGT-1BTYiZ0TrYPNB7Vozw2ljWwXDd-6W6H8l2crYIAKFGojLt62jl83ff9UOnnOo201fmv4LeWk9sz_cfIHgG7AT3hOmffGzBH381dfhMXXMu_VLSDGN1rRDQ/s1600/Lupine+Publishers-Interventions+in+Gynaecology+and+Women%25E2%2580%2599s+Healthcare.jpg)
Immunotherapy in Ovarian Cancer by Satyendra C Tripathi in IGWHC in Lupine Publishers Ovarian cancer ranks fifth with a 5-year survival of 40% for patients with advanced disease and remains the most lethal gynecologic malignancy among women [1]. Most patients with advanced disease undergo aggressive frontline treatments with surgery and adjuvant chemotherapy; however, 80% of patients ultimately recur within few months and develop chemoresistant disease [2]. Advances in traditional treatment regimens and addition bevacizumab as a targeted therapy have shown promising results with improved progression-free survival but overall survival rates still remains the unaltered. http://www.lupinepublishers.com/gynecology-women-health-journal/abstracts/immunotherapy-in-ovarian-cancer.ID.000112.php http://www.lupinepublishers.com/gynecology-women-health-journal/fulltext/immunotherapy-in-ovarian-cancer.ID.000112.php For more Lupine Publishers Open Access Journals Please visit ou...